A Fujimasa, T Fukushima, S Yuge, M Tanaka, T Koga, Y Nishimura, J Takeda, T Kakegawa, I Fukushima, S Yuge
{"title":"[Serum levels of beta-seminoprotein (beta-Sm) in patients with breast cancer].","authors":"A Fujimasa, T Fukushima, S Yuge, M Tanaka, T Koga, Y Nishimura, J Takeda, T Kakegawa, I Fukushima, S Yuge","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Serum levels of beta-Sm (a component of human seminal plasma) were measured in patients with breast cancer or mastopathy by RIA method. 9.4 +/- 9.5 ng/ml in control healthy adult women and 11.7 +/- 15.7 ng/ml in 8 patients with mastopathy were observed. Whereas, in 30 patients with breast cancer including 28 pre-operation and 2 recurrence 64.5 +/- 52.3 ng/ml were observed. Especially, high levels of beta-Sm (135.8 and 182.3 ng/ml) in the recurrence were detected. Each case of 8 post-operation was below 50 ng/ml. Fifty-seven percent of patients with breast cancer including pre-operation and recurrence were showed over 50 ng/ml. In histological typing, the beta-Sm levels of papillotubular carcinoma were higher than that of scirrhous carcinoma. In tubular carcinoma, 45% of stage I, 67% of stage II and 100% of stage III, IV and recurrence cases were over 50 ng/ml. The evidence suggests that serum levels of beta-Sm is useful for the diagnosis of breast cancer.</p>","PeriodicalId":76232,"journal":{"name":"Nihon Gan Chiryo Gakkai shi","volume":"25 10","pages":"2511-8"},"PeriodicalIF":0.0000,"publicationDate":"1990-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nihon Gan Chiryo Gakkai shi","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Serum levels of beta-Sm (a component of human seminal plasma) were measured in patients with breast cancer or mastopathy by RIA method. 9.4 +/- 9.5 ng/ml in control healthy adult women and 11.7 +/- 15.7 ng/ml in 8 patients with mastopathy were observed. Whereas, in 30 patients with breast cancer including 28 pre-operation and 2 recurrence 64.5 +/- 52.3 ng/ml were observed. Especially, high levels of beta-Sm (135.8 and 182.3 ng/ml) in the recurrence were detected. Each case of 8 post-operation was below 50 ng/ml. Fifty-seven percent of patients with breast cancer including pre-operation and recurrence were showed over 50 ng/ml. In histological typing, the beta-Sm levels of papillotubular carcinoma were higher than that of scirrhous carcinoma. In tubular carcinoma, 45% of stage I, 67% of stage II and 100% of stage III, IV and recurrence cases were over 50 ng/ml. The evidence suggests that serum levels of beta-Sm is useful for the diagnosis of breast cancer.